5-methyltetrahydrohomofolate Peter J. O'DwyerBarbara H. WagnerBrian Leyland-Jones New Agent Review Pages: 215 - 218
Drug sensitivity of ten human tumor cell lines compared to mouse leukemia (L1210) cells Gloria J. BadinerRamon D. HamiltonBijoy K. Bhuyan Preclinical Studies Pages: 219 - 229
Comparative in vitro activity of 4′-deoxy-4′-iododoxorubicin and other anthracyclines in the human tumor clonogenic assay Jonathan E. SchwartzSydney E. Salmon Preclinical Studies Pages: 231 - 234
Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390) G. J. PetersS. L. SharmaH. M. Pinedo Preclinical Studies Pages: 235 - 244
Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay Maria Grazia DaidoneRosella SilvestriniFabio Landoni Preclinical Studies Pages: 245 - 250
Cyclosporine and α-difluoromethylornithine exhibit differential effects on colon and pancreatic cancer in vitro Rami SaydjariCourtney M. Townsend Jr.James C. Thompson Preclinical Studies Pages: 251 - 258
Inactivation of human cells cultivated in vitro by the new mitotic inhibitors NY 4137 and NY 4138 Mina E. Holm NygaardErik O. PettersenReidar Oftebro Preclinical Studies Pages: 259 - 266
Release of methyl isocyanate from the antitumor agent caracemide (NSC-253272) Robert A. NewmanDavid Farquhar Pharmacology Studies Pages: 267 - 271
Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry M. C. Malet-MartinoP. ServinR. Martino Pharmacology Studies Pages: 273 - 279
Enhancement of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) toxicity by acetohydroxamic acid analogues of 3-nitropyrazole in vitro R. Timothy MulcahyDavid J. WustrowAndrew S. Kende Pharmacology Studies Pages: 281 - 287
Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma David S. AlbertsNancy Mason-LiddilRobert B. Epstein Phase II Clinical Trials Pages: 289 - 292
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma David A. AmatoHoward BrucknerThomas J. Cunningham Phase II Clinical Trials Pages: 293 - 297
A phase II study of (2″ R)-4′ -0-tetrahydropyranyladriamycin (THP) in hematological malignancies Kazumasa YamadaShigeru ShirakawaKiyoji Kimura Phase II Clinical Trials Pages: 299 - 305
Phase II study of esorubicin (4′ -deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma Sergio FrustaciGiampietro GaspariniSilvio Monfardini Phase II Clinical Trials Pages: 307 - 309